Triple-negative breast cancer: New therapeutic options via signalling transduction cascades

被引:9
作者
Andergassen, Ulrich [1 ]
Koelbl, Alexandra C. [1 ]
Mumm, Jan-Niclas [1 ]
Mahner, Sven [1 ]
Jeschke, Udo [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Obstet & Gynaecol, Maistr 11, D-80337 Munich, Germany
关键词
triple-negative breast cancer; signal transduction cascades; cancer treatment; immunohistochemistry; statistical analysis; tumour traits; recurrence; BETA-CATENIN; METASTATIC BEHAVIOR; EXPRESSION; SURVIVAL; NOTCH1; CHEMOTHERAPY; BEVACIZUMAB; PATHWAYS; EFFICACY; CELLS;
D O I
10.3892/or.2017.5512
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer is a highly aggressive type of mammalian carcinoma. It is defined by a rather weak expression of estrogen-, progesterone- and Her2-receptor, and is thus difficult to treat, resulting in low disease-free and overall survival rates of the affected patients. Hence it is important to find new therapeutic options. To this aim we analysed the incidence of some molecules from different signal transduction cascades by immunohistochemistry, which are known to correlate with triple-negative breast cancer, and correlated the expression of these molecules to different tumour traits, such as size, grading, menopausal stage, histology, lymph node affection, remote metastasis formation, and to the incidence of local and lymph node recurrence and metastasis by statistical analysis. Statistically significant correlations were found for a number of tumour characteristics and signalling molecules: HIF1 alpha is correlated to tumour grading, beta-catenin to the menopausal state of the patient, and for Notchl a relation to lymph node affection is seen. In terms of different recurrences, a correlation of beta-catenin to metastasis formation-and lymph node affection could be shown, as well as coherences between XBP1 and lymph node recurrence, Notchl and metastasis formation and FOXP3 and the occurrence of local recurrence. The presented results are in accordance with formerly published studies and therefore might comprise opportunities to develop new therapeutical strategies, which could help to handle this aggressive form of breast cancer in a manner, by which side effects would be reduced and therapeutical efficiency is increased.
引用
收藏
页码:3055 / 3060
页数:6
相关论文
共 40 条
  • [1] [Anonymous], 2015, KREBS DEUTSCHL 2011
  • [2] Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
    Badve, Sunil
    Dabbs, David J.
    Schnitt, Stuart J.
    Baehner, Frederick L.
    Decker, Thomas
    Eusebi, Vincenzo
    Fox, Stephen B.
    Ichihara, Shu
    Jacquemier, Jocelyne
    Lakhani, Sunil R.
    Palacios, Jose
    Rakha, Emad A.
    Richardson, Andrea L.
    Schmitt, Fernando C.
    Tan, Puay-Hoon
    Tse, Gary M.
    Weigelt, Britta
    Ellis, Ian O.
    Reis-Filho, Jorge S.
    [J]. MODERN PATHOLOGY, 2011, 24 (02) : 157 - 167
  • [3] Cetuximab plus Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial
    Baselga, J.
    Stemmer, S.
    Pego, A.
    Chan, A.
    Goeminne, J-C
    Graas, M-P
    Kennedy, J.
    Gil, E. M. Ciruelos
    Zubel, A.
    Groos, J.
    Kia, U.
    Schneeweiss, A.
    [J]. CANCER RESEARCH, 2010, 70
  • [4] Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?
    Brenton, JD
    Carey, LA
    Ahmed, AA
    Caldas, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (29) : 7350 - 7360
  • [5] Implications of the Notch1-Snail/Slug-epithelial to mesenchymal transition axis for lymph node metastasis in infiltrating ductal carcinoma
    Cao, Yu-Wen
    Wan, Guo-Xing
    Sun, Jian-Ping
    Cui, Xiao-Bin
    Hu, Jian-Ming
    Liang, Wei-Hua
    Zheng, Yu-Qin
    Li, Wen-Qin
    Li, Feng
    [J]. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2015, 31 (02) : 70 - 76
  • [6] Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer
    Cao, Yu-Wen
    Li, Wen-Qin
    Wan, Guo-Xing
    Li, Yi-Xiao
    Du, Xiao-Ming
    Li, Yu-Cong
    Li, Feng
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
  • [7] XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
    Chen, Xi
    Iliopoulos, Dimitrios
    Zhang, Qing
    Tang, Qianzi
    Greenblatt, Matthew B.
    Hatziapostolou, Maria
    Lim, Elgene
    Tam, Wai Leong
    Ni, Min
    Chen, Yiwen
    Mai, Junhua
    Shen, Haifa
    Hu, Dorothy Z.
    Adoro, Stanley
    Hu, Bella
    Song, Minkyung
    Tan, Chen
    Landis, Melissa D.
    Ferrari, Mauro
    Shin, Sandra J.
    Brown, Myles
    Chang, Jenny C.
    Liu, X. Shirley
    Glimcher, Laurie H.
    [J]. NATURE, 2014, 508 (7494) : 103 - +
  • [8] Triple-Negative Breast Cancer Epidemiology and Management Options
    Dawood, Shaheenah
    [J]. DRUGS, 2010, 70 (17) : 2247 - 2258
  • [9] Oridonin Inhibits Tumor Growth and Metastasis through Anti-Angiogenesis by Blocking the Notch Signaling
    Dong, Yanmin
    Zhang, Tao
    Li, Jingjie
    Deng, Huayun
    Song, Yajuan
    Zhai, Dong
    Peng, Yi
    Lu, Xiaoling
    Liu, Mingyao
    Zhao, Yongxiang
    Yi, Zhengfang
    [J]. PLOS ONE, 2014, 9 (12):
  • [10] Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
    Grob, Tobias J.
    Heilenkoetter, Uwe
    Geist, Stefan
    Paluchowski, Peter
    Wilke, Christian
    Jaenicke, Fritz
    Quaas, Alexander
    Wilczak, Waldemar
    Choschzick, Matthias
    Sauter, Guido
    Lebeau, Annette
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (02) : 561 - 567